type 2 diabetes
Start metformin first for most patients, but let cardiorenal risk drive the second drug immediately — even if A1C is already at target. Metabolic decompensation or catabolic symptoms → insulin first. Add SGLT2 inhibitors for HF or CKD, and GLP-1 receptor agonists (or tirzepatide) when ASCVD, weight loss, or potent A1C lowering dominate.
initial therapy and treatment algorithm
Assess metabolic stability first, then cardiorenal comorbidities, then glycaemic gap and patient priorities. Reassess A1C every 3–6 months and cardiorenal status at least annually.
flowchart TD
A["new or uncontrolled T2DM"] --> B{"metabolic decompensation?\n(ketosis, HHS, weight loss,\nsevere osmotic symptoms)"}
B -- yes --> C["start insulin ± metformin\ntaper insulin once stable"]
B -- no --> D["health behaviours + metformin\n(start 250–500 mg BID → 2000 mg/day)"]
D --> E{"ASCVD, high CV risk,\nHF, or CKD?"}
E -- yes --> F["add proven cardiorenal agent\nregardless of A1C"]
F --> F1["HFrEF / HFmrEF / HFpEF → SGLT2i\n(add GLP-1 RA / tirzepatide if BMI ≥30 + HFpEF)"]
F --> F2["CKD → SGLT2i (first); add semaglutide\nor finerenone if persistent albuminuria"]
F --> F3["ASCVD / high CV risk → GLP-1 RA\nand/or SGLT2i with proven MACE benefit"]
E -- no --> G{"A1C >1.5% above target\nor still above target?"}
G -- yes --> H["choose add-on by priority:\nweight/A1C → tirzepatide or semaglutide\nlow hypo risk / oral → SGLT2i or DPP-4i\ncost → gliclazide"]
- Metabolic decompensation (ketosis, HHS, unintentional weight loss, severe polyuria/polydipsia) → insulin immediately ± metformin regardless of A1C (ADA 2026 also flags A1C >10% or BG ≥16.7 mmol/L). Once glucotoxicity resolves, taper insulin if non-insulin agents maintain targets.
- A1C >1.5% above target without decompensation → initial combination therapy (metformin + second agent) reaches A1C <7% faster than sequential escalation.
- Metformin titration: start 250–500 mg BID with meals → titrate over weeks to 2,000 mg/day (little extra A1C lowering above 2 g/day; switch to ER for GI intolerance). Check vitamin B12 periodically or with neuropathy/anaemia.
- Never combine overlapping mechanisms: no DPP-4i with GLP-1 receptor agonists or GIP/GLP-1 RA; no sulfonylurea with meglitinide.
choosing the cardiorenal or second-line agent
Cardiorenal agents are indicated independent of A1C when comorbidities exist (Diabetes Canada 2024, ADA 2026). When a patient has both ASCVD and CKD or HF, combining an SGLT2i and a GLP-1 RA gives additive protection.
| comorbidity / priority | preferred agent(s) | evidence & nuances |
|---|---|---|
| HFrEF (LVEF ≤40%) | empagliflozin or dapagliflozin | Grade A for CV death + HF hospitalisation; avoid saxagliptin and pioglitazone (↑ HF); liraglutide showed ↑ HF events in acute HFrEF |
| HFpEF / HFnrEF (LVEF >40%) | empagliflozin or dapagliflozin | add semaglutide or tirzepatide if obesity (BMI ≥30) for symptoms and worsening HF events (ADA 2026, HFnrEF management) |
| CKD (eGFR <60 or uACR ≥2.0) | empagliflozin, dapagliflozin, or canagliflozin | DC 2025 keeps diabetic albuminuria at uACR ≥2.0 mg/mmol (KDIGO/ADA: ≥3.0); add semaglutide (eGFR ≥25 + elevated uACR; FLOW — ↓ kidney progression and CV death) and/or finerenone (eGFR ≥25, uACR ≥3, K⁺ ≤4.8) → chronic kidney disease |
| ASCVD / high CV risk | dulaglutide, liraglutide, SC semaglutide, empagliflozin, or canagliflozin | SGLT2i (empagliflozin/dapagliflozin) carry strongest CV mortality data; GLP-1 RAs give stronger stroke reduction. Exenatide, lixisenatide, and ertugliflozin lack proven MACE superiority |
| weight loss & potent A1C lowering | tirzepatide > semaglutide > liraglutide / dulaglutide | tirzepatide gives the largest A1C and weight reductions (~15–20%); no dedicated CKD/CVOT published yet vs semaglutide |
| MASLD / MASH | semaglutide, tirzepatide, or pioglitazone | improves steatohepatitis; see MASLD |
| cost-constrained | gliclazide (preferred SU) or pioglitazone | avoid glyburide (severe hypoglycaemia); pioglitazone causes oedema, weight gain, fractures, and HF |
SGLT2 inhibitors, GLP-1 RAs, and tirzepatide lack human pregnancy safety data — avoid or discontinue in patients who are pregnant, planning pregnancy, or without reliable contraception (→ diabetes in pregnancy).
renal dosing by eGFR
Glucose-lowering efficacy of SGLT2 inhibitors falls sharply below eGFR 45 mL/min/1.73 m², but cardiorenal protection persists down to dialysis.
| eGFR (mL/min/1.73 m²) | metformin (DC 2024 vs ADA 2026) | SGLT2i | GLP-1 RA / tirzepatide | DPP-4i | secretagogues & insulin |
|---|---|---|---|---|---|
| ≥60 | max 2,550 mg (2,000 mg ER) | full dose | full dose | full dose | full dose |
| 45–59 | max 2,550 mg; monitor eGFR | cana 100 mg; empa 10 mg; dapa 10 mg | no change | no change | avoid glyburide; others unchanged |
| 30–44 | max 1,000 mg/day | cana 100 mg; empa 10 mg; dapa 10 mg | no change | lina 5; sita 50; saxa 2.5 | avoid glyburide; insulin may need ↓ dose |
| 15–29 | DC 2024: 500 mg/day; ADA/KDIGO: stop <30 | do not initiate if cana <30, dapa <25, empa <20; continue if already on | no change | lina 5; sita 25; saxa 2.5 | ↓ gliclazide/repaglinide dose; ↓ insulin |
| <15 or dialysis | avoid (lactic acidosis) | stop on dialysis | limited data | lina 5 mg; sita 25 mg; avoid saxa | avoid secretagogues; ↓ insulin |
Diabetes Canada 2024 permits metformin 500 mg/day down to eGFR 15 with closer monitoring, whereas ADA 2026 and KDIGO 2022 contraindicate metformin below eGFR 30. In practice, hold metformin during AKI, sepsis, contrast with AKI risk, or tissue hypoxia (sick-day rules).
insulin initiation and intensification
When non-insulin agents fail to meet A1C targets, consider a GLP-1 RA or tirzepatide before insulin unless catabolic hyperglycaemia is present (ADA 2026).
- Start basal insulin once daily (0.1–0.2 U/kg or 10 U daily) and titrate by 1–2 U every 3 days to fasting glucose target (4.0–7.0 mmol/L).
- Long-acting analogues (glargine U-100/U-300, detemir, degludec) reduce nocturnal hypoglycaemia vs NPH (Grade A); degludec or glargine U-300 further reduce nocturnal/severe hypoglycaemia in high-risk patients.
- Continue metformin, SGLT2i, and GLP-1 RA — lowers insulin dose, weight gain, and hypoglycaemia (Grade A).
- Add prandial (bolus) insulin stepwise (“basal-plus”): start 1 injection (e.g. 4 U or 10% of basal) at the largest meal and titrate to 2-hour postprandial glucose before advancing to full basal-bolus.
- Stop sulfonylureas and meglitinides once bolus or premixed insulin starts (hypoglycaemia risk).
- Watch for overbasalisation (basal >0.5 U/kg/day, bedtime-to-morning glucose drop ≥2.8 mmol/L, or fasting hypoglycaemia with elevated A1C) → add prandial therapy rather than pushing basal higher.
remission and deprescribing
- Remission (A1C <6.5% off all glucose-lowering drugs for ≥3 months; <6.0% for normoglycaemia; pursue only if no compelling cardiorenal indication to stay on glucose-lowering therapy and no eating/significant mental health disorder): bariatric surgery (non-pregnant T2DM with BMI ≥35, Grade A) or intensive low-calorie meal replacement (~800–850 kcal/day for 3–5 months + structured food reintroduction/activity targeting >15 kg loss in early T2DM <6 years, non-insulin-treated, BMI 27–45, A1C <12%, Grade A). Monitor A1C every 6 months for relapse.
- Older adults and frailty: relax A1C targets (7.1–8.0% functionally dependent; 7.1–8.5% frail/dementia — the 7.1% floor applies when on insulin or sulfonylureas; <8.0% / <8.5% on low-risk agents → diabetes — diagnosis, targets, and complications) and deprescribe sulfonylureas or excess insulin first. Prefer DPP-4i over sulfonylureas in frail older adults; if a sulfonylurea is used, choose gliclazide at half the starting dose and avoid glyburide.
- Ontario: ODB covers SC semaglutide (Ozempic) via LU 665–667 and oral semaglutide (Rybelsus) via LU 662–664 / 738–740 for T2DM uncontrolled on max tolerated metformin; SGLT2 inhibitors are general benefit; tirzepatide and obesity-dose semaglutide are not ODB-funded.
Prepared 2026-11-19. Not yet verified — check every number against the sources.